Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of autoimmune diseases, including multiple sclerosis. Tcelna® is a patient specific T-cell immunotherapy being developed for the treatment of multiple sclerosis (MS), and is specifically tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTC) known to attack myelin. Tcelna is manufactured using ImmPath®, Opexa Therapeutics’ proprietary method for the production of an autologous T-cell product, which comprises the collection of blood from the MS patient and the expansion of MRTC from the blood. On completion of the manufacturing process, MRTC are formulated and attenuated by irradiation before returning the final product to the clinical site for subcutaneous administration to the patient, with the express purpose of inducing a regulatory immune response to impede immunity to myelin.
Read about this research study and Find study center locations, HERE
……..
To comment – click the comment link shown below
…….
Share our Articles with others
…….
Share our Articles with others
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
